TECNIS PureSee IOL launches in US following FDA approval for cataract surgery

Johnson & Johnson has begun the full US commercial rollout of the TECNIS PureSee intraocular lens (IOL), a purely refractive extended depth-of-focus (EDOF) lens cleared by the US Food and Drug Administration in March 2026 for use in cataract surgery.^1-3 For cataract surgeons, the lens adds another presbyopia-correcting option positioned between standard monofocals and diffractive multifocal designs, with a stated emphasis on preserving contrast sensitivity rather than maximizing near vision.^2,4

The clinical proposition is incremental rather than transformative: pivotal and supporting data describe statistically improved intermediate (and, to a lesser degree, near) acuity versus a monofocal comparator, while distance acuity, contrast sensitivity, and dysphotopsia profile remain comparable to a monofocal lens.^1,4

Regulatory and trial overview

The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026. The approved indication is primary implantation for the visual correction of aphakia in adults with less than 1 diopter (D) of preexisting corneal astigmatism following cataract removal, with capsular bag placement only. A companion toric version (TECNIS PureSee Toric II) is indicated for eyes with 1 D or more of preoperative corneal astigmatism.³

The US pivotal study summarized in the FDA Summary of Safety and Effectiveness Data was a prospective, bilateral, randomized, subject- and evaluator-masked, multicenter trial. Of 245 enrolled patients, 228 were bilaterally implanted (115 PureSee, 113 monofocal control), with 6-month follow-up available for roughly 98% of implanted patients; the prespecified co-primary safety endpoints were met.¹ Two peer-reviewed reports of a separate prospective, randomized study conducted in Australia and New Zealand (NCT04890249) compared PureSee against the TECNIS Eyhance enhanced monofocal.^4-6 In that study, mean corrected distance acuity was comparable between lenses (−0.06 vs −0.05 logMAR), while distance-corrected intermediate acuity (0.13 vs 0.18 logMAR; P = .0127) and distance-corrected near acuity (0.37 vs 0.43 logMAR; P = .0137) favored PureSee.⁴ Mesopic contrast sensitivity fell within roughly 0.11 log units of the monofocal across all spatial frequencies, and most patients reported little or no bother from halos, starbursts, or glare.⁴ The company additionally reports that 97% of patients experienced no very bothersome visual disturbances.^2,3

Clinical context

Cataract remains the leading global cause of moderate-to-severe distance vision impairment and blindness, affecting an estimated 94 million people, and cataract extraction with IOL implantation is among the most commonly performed and cost-effective surgical procedures worldwide.⁸ Presbyopia, the age-related loss of accommodative near focus, is effectively universal in those who reach their sixth decade and affects an estimated 1.8 billion people globally.⁹ Standard aspheric monofocal IOLs reliably restore distance vision but leave most patients dependent on spectacles for intermediate and near tasks. Diffractive multifocal and trifocal IOLs broaden range but carry a recognized trade-off in contrast sensitivity and photic phenomena. EDOF lenses were developed to occupy the middle ground, extending a single elongated focus to improve intermediate function while limiting dysphotopsia.

Device and drug-class background

The TECNIS PureSee is a single-piece hydrophobic acrylic lens built on the established TECNIS platform. Unlike diffractive EDOF designs such as the TECNIS Symfony, which uses an echelette diffractive surface, PureSee achieves extended depth of focus through a purely refractive, continuously varying posterior curvature, paired with a wavefront-designed aspheric anterior surface intended to neutralize corneal spherical aberration.^4,5 The TECNIS family already includes the Symfony diffractive EDOF, the Eyhance enhanced monofocal, and the Odyssey full–visual-range lens.² According to the manufacturer, PureSee is the first and only US EDOF IOL approved without a labeling warning regarding loss of contrast sensitivity—a regulatory labeling distinction based on demonstrating no clinically meaningful difference (≤0.3 log units) from an aspheric monofocal, rather than evidence of superiority over other presbyopia-correcting lenses.^1-3

Limitations and next steps

Reported outcomes derive largely from 6-month follow-up, limiting conclusions about longer-term refractive stability, posterior capsule opacification, and explantation rates.^1,4 Several supporting datasets presented at ASCRS 2026 are real-world, single-arm observational cohorts rather than randomized comparisons, and patient-satisfaction figures originate substantially from manufacturer communications.⁷ Head-to-head trials against other non-diffractive EDOF lenses (e.g., Clareon Vivity) are ongoing or planned and will better define comparative positioning.⁶ Independent, peer-reviewed US outcomes and longer-term safety data will be important to corroborate the contrast-sensitivity and dysphotopsia advantages emphasized in current labeling and company materials.

References

1. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): TECNIS PureSee IOL. PMA P980040/S176. 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf/P980040S176B.pdf

2. Johnson & Johnson. Johnson & Johnson announces FDA approval of TECNIS PureSee intraocular lens, a breakthrough solution for U.S. cataract patients. March 12, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients

3. Johnson & Johnson. Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL. June 11, 2026. https://www.businesswire.com/news/home/20260611210092/en/Johnson-Johnson-Expands-U.S.-Availability-of-TECNIS-PureSee-IOL-an-Advanced-Lens-Option-for-Cataract-Surgeons-and-Patients

4. Vilupuru S, et al. Quality of vision clinical outcomes for a new fully-refractive extended depth of focus intraocular lens. Eye (Lond). 2024;38(1):9-14. doi:10.1038/s41433-024-03039-8. https://doi.org/10.1038/s41433-024-03039-8

5. Vilupuru S, et al. Tolerance to refractive error with a new extended depth of focus intraocular lens. Eye (Lond). 2024;38(1):15-20. doi:10.1038/s41433-024-03040-1. https://doi.org/10.1038/s41433-024-03040-1

6. ClinicalTrials.gov. Clinical investigation of the TECNIS PureSee (ZEN00V) IOL. Identifier NCT04890249. https://clinicaltrials.gov/study/NCT04890249

7. Johnson & Johnson. Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL at ASCRS 2026. April 10, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-new-clinical-data-for-tecnis-puresee-iol-at-ascrs-2026-demonstrating-excellent-contrast-sensitivity-and-extended-range-of-vision

8. World Health Organization. Blindness and vision impairment. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment

9. McCormick I, et al. Presbyopia: addressing an urgent global need. Community Eye Health J. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141125/